Core Insights - Grace Therapeutics, Inc. is a late-stage biopharma company focused on developing GTx-104, an injectable formulation of nimodipine for IV infusion targeting aSAH patients [1][4] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, with opportunities for one-on-one meetings with institutional investors [2][3] Company Overview - Grace Therapeutics specializes in drug candidates for rare and orphan diseases, with innovative drug delivery technologies aimed at improving drug performance [4] - The lead clinical asset, GTx-104, has received Orphan Drug Designation from the FDA, granting seven years of marketing exclusivity post-launch in the U.S. and additional intellectual property protection with over 40 patents [4] Conference Details - The conference will be held at the Lotte New York Palace Hotel, featuring over 550 company presentations available live or on demand [2] - Prashant Kohli, CEO of Grace Therapeutics, will be available for one-on-one meetings with institutional investors during the event [2]
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference